BACKGROUND: Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid leukemia (CML), there is a dearth of information on their impact on patients' health-related quality of life (HRQOL). The primary objective of this study was to evaluate HRQOL and fatigue outcomes in patients with CML receiving first-line therapy with nilotinib. METHODS: This was a multicenter, prospective study enrolling 130 patients with chronic-phase CML. HRQOL and fatigue were evaluated with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and its validated Fatigue module at the baseline and then at 3, 6, 12, 18, and 24 months. The primary prespecified HRQOL endpoints defined in the study protocol for longitudinal analysis were the Physical Functioning, Social Functioning, Role Functioning, and Fatigue scales. The remaining scales were investigated on an exploratory basis. RESULTS: The rate of baseline compliance with the HRQOL assessment was 95.4% (124 of 130), and the rate of overall compliance with HRQOL forms was 91%. Among the 4 prespecified primary HRQOL endpoints, statistically significant improvements over time were found for Physical Functioning (P =.013), Role Functioning (P =.004), and Fatigue (P <.001). Clinically meaningful improvements were found already 3 months after the treatment start. The baseline patient self-reported fatigue severity was an independent predictive factor for the achievement of a major molecular response with an odds ratio of 0.960 (95% confidence interval, 0.934-0.988; P =.005). CONCLUSIONS: For most patients, HRQOL improvements with nilotinib occur during the early phase of therapy and are maintained over time. Also, a more systematic HRQOL evaluation during the diagnostic workup of CML may help to predict clinical outcomes. Cancer 2018;124:2228-37. © 2018 American Cancer Society.

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib / Efficace, Fabio; Castagnetti, Fausto; Martino, Bruno; Breccia, Massimo; D'Adda, Mariella; Angelucci, Emanuele; Stagno, Fabio; Cottone, Francesco; Malato, Alessandra; Trabacchi, Elena; Capalbo, Silvana Franca; Gobbi, Marco; Visani, Giuseppe; Salvucci, Marzia; Capodanno, Isabella; Tosi, Patrizia; Tiribelli, Mario; Scortechini, Anna Rita; Levato, Luciano; Maino, Elena; Binotto, Gianni; Gugliotta, Gabriele; Vignetti, Marco; Baccarani, Michele; Rosti, Gianantonio. - In: CANCER. - ISSN 0008-543X. - 124:10(2018), pp. 2228-2237. [10.1002/cncr.31323]

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib

Efficace, Fabio;Cottone, Francesco;Vignetti, Marco;
2018

Abstract

BACKGROUND: Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid leukemia (CML), there is a dearth of information on their impact on patients' health-related quality of life (HRQOL). The primary objective of this study was to evaluate HRQOL and fatigue outcomes in patients with CML receiving first-line therapy with nilotinib. METHODS: This was a multicenter, prospective study enrolling 130 patients with chronic-phase CML. HRQOL and fatigue were evaluated with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and its validated Fatigue module at the baseline and then at 3, 6, 12, 18, and 24 months. The primary prespecified HRQOL endpoints defined in the study protocol for longitudinal analysis were the Physical Functioning, Social Functioning, Role Functioning, and Fatigue scales. The remaining scales were investigated on an exploratory basis. RESULTS: The rate of baseline compliance with the HRQOL assessment was 95.4% (124 of 130), and the rate of overall compliance with HRQOL forms was 91%. Among the 4 prespecified primary HRQOL endpoints, statistically significant improvements over time were found for Physical Functioning (P =.013), Role Functioning (P =.004), and Fatigue (P <.001). Clinically meaningful improvements were found already 3 months after the treatment start. The baseline patient self-reported fatigue severity was an independent predictive factor for the achievement of a major molecular response with an odds ratio of 0.960 (95% confidence interval, 0.934-0.988; P =.005). CONCLUSIONS: For most patients, HRQOL improvements with nilotinib occur during the early phase of therapy and are maintained over time. Also, a more systematic HRQOL evaluation during the diagnostic workup of CML may help to predict clinical outcomes. Cancer 2018;124:2228-37. © 2018 American Cancer Society.
chronic myeloid leukemia; fatigue; nilotinib; quality of life; tyrosine kinase inhibitors; Oncology; Cancer Research
01 Pubblicazione su rivista::01a Articolo in rivista
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib / Efficace, Fabio; Castagnetti, Fausto; Martino, Bruno; Breccia, Massimo; D'Adda, Mariella; Angelucci, Emanuele; Stagno, Fabio; Cottone, Francesco; Malato, Alessandra; Trabacchi, Elena; Capalbo, Silvana Franca; Gobbi, Marco; Visani, Giuseppe; Salvucci, Marzia; Capodanno, Isabella; Tosi, Patrizia; Tiribelli, Mario; Scortechini, Anna Rita; Levato, Luciano; Maino, Elena; Binotto, Gianni; Gugliotta, Gabriele; Vignetti, Marco; Baccarani, Michele; Rosti, Gianantonio. - In: CANCER. - ISSN 0008-543X. - 124:10(2018), pp. 2228-2237. [10.1002/cncr.31323]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1189548
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 18
social impact